A Phase I, Open-Label, Single Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of PD-0332334 In Subjects Receiving Chronic Hemodialysis.

Trial Profile

A Phase I, Open-Label, Single Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of PD-0332334 In Subjects Receiving Chronic Hemodialysis.

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Oct 2009

At a glance

  • Drugs Imagabalin (Primary)
  • Indications Generalised anxiety disorder
  • Focus Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 30 Oct 2009 Actual initiation date changed from Oct 2008 to Sep 2008 as reported by ClinicalTrials.gov.
    • 16 Jan 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 16 Jan 2009 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top